Vireo Growth Inc. has officially filed a proxy statement regarding its proposed merger with Planet 13 Holdings Inc. This significant move is set to reshape the landscape of the pharmaceutical preparations industry, as Vireo seeks to bolster its market presence through this strategic acquisition. The merger proposal is scheduled for a stockholder vote on December 10, 2026, where shareholders will determine the future of this ambitious endeavor.

Vireo Growth Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is an emerging growth company. It operates primarily on the OTC exchange under the ticker symbol VREOF. The company has recently undergone a name change from Goodness Growth Holdings, Inc., reflecting its evolving strategy and focus within the industry. The filing of the proxy statement on November 2, 2026, marks a crucial step in the merger process, following a series of recent filings that indicate Vireo's commitment to this transaction.

The filing outlines the terms of the merger agreement, which was initially entered into on July 26, 2026. Under this agreement, Vireo's wholly-owned subsidiary, Supernova Merger Sub Inc., will merge with Planet 13, with Planet 13 continuing as a subsidiary of Vireo Growth. Shareholders of Planet 13 will receive 0.015383618 of a subordinate voting share of Vireo Growth for each share of Planet 13 common stock they hold. This exchange ratio is designed to reflect the valuation of both companies and ensure a fair transition for shareholders.

According to the filing, if the merger is completed, current shareholders of Vireo Growth will own approximately 90.62% of the outstanding subordinate voting shares, while Planet 13 shareholders will hold about 9.38%. This distribution underscores Vireo's dominant position post-merger, enhancing its footprint in the pharmaceutical preparations sector.

The merger proposal requires approval from Planet 13 stockholders, necessitating a majority vote at the upcoming special meeting. This meeting will be conducted virtually, allowing stockholders to participate from anywhere. The record date for eligible voters is set for October 29, 2026, ensuring that those who hold shares at that time can voice their opinions on the merger.

In preparation for the vote, Vireo Growth has entered into voting agreements with key shareholders of Planet 13, who collectively own a substantial portion of the company's stock. These agreements are designed to secure the necessary votes in favor of the merger, demonstrating Vireo's strategic approach to ensuring a smooth transition and successful integration.

The Planet 13 board of directors, guided by a special committee of independent directors, has reviewed the merger agreement and unanimously recommended its approval. The committee believes that the merger is in the best interests of Planet 13 shareholders, particularly those not affiliated with the company's founders. This endorsement is critical as it adds credibility to the merger proposal and may influence the voting outcome.

As the date for the special meeting approaches, both companies are preparing to address any concerns from shareholders and provide detailed information regarding the merger's implications. The proxy statement serves as a comprehensive guide for stockholders, outlining the benefits and risks associated with the merger.

Looking ahead, the outcome of the stockholder vote on December 10, 2026, will be pivotal for Vireo Growth and Planet 13. If approved, the merger is expected to enhance Vireo's market position and expand its product offerings within the pharmaceutical preparations industry. However, the filing does not specify what happens next if the proposal is approved or rejected, leaving stakeholders awaiting further developments.